TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29921734
Drug: Intravenous epoetin
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous epoetin alfa-epbx
Study: 29921734
Drug: Intravenous epoetin
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous epoetin alfa
Study: 24925713
Drug: Docosahexaenoic acid-enriched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docosahexaenoic acid-enriched fish oil (600 mg daily)
Study: 22250633
Drug: Auricular acupuncture
Normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auricular acupuncture (weekly for 10 weeks)
Study: 22250633
Drug: 0.1% tretinoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% tretinoin ointment (topically for 10 weeks)
Study: 11794427
Drug: Step-down therapy
Normalized name: Kool-Down
Approvals — FDA: no, EMA: no, PMDA: no
Description: Step-down therapy with pravastatin (dosing frequency changed from daily to every other day)
Study: 11794427
Drug: Step-down therapy
Normalized name: Kool-Down
Approvals — FDA: no, EMA: no, PMDA: no
Description: Step-down therapy with pravastatin (daily dose halved)
Study: 10463515
Drug: Sparfloxacin 200/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sparfloxacin 200/100 mg
Study: 10463515
Drug: Sparfloxacin 400/200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sparfloxacin 400/200 mg
Study: 10463515
Drug: Sparfloxacin 800/400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sparfloxacin 800/400 mg
Study: 7615103
Drug: Dopamine (DA)
DrugBank: Dopamine (DB00988)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dopamine (DA) infusion (0.4 micrograms/kg per minute)
Study: 1696309
Drug: Chemotherapy (CT)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (CT) - two cycles of cisplatin, vindesine, and bleomycin
Study: 1696309
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy (RT) - 55 Gy
Study: 18524792
Drug: Adalimumab treatment
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab treatment for 24 weeks
Study: 16326406
Drug: Transcatheter arterial
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcatheter arterial chemoembolization (TACE) with Adriamycin (20 mg/m2), vincristine (1.5 mg/m2), and cisplatin (40 mg/m2) dispersed in 5-10 mL lipiodol, performed 1-3 times.
Study: 15235875
Drug: Iron reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron reduction therapy by biweekly phlebotomy for 3 months
Study: 28941216
Drug: ABT-122 1
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-122 1 mg/kg every other week (4 doses)
Study: 28941216
Drug: ABT-122 0.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-122 0.5, 1.5, or 3 mg/kg weekly (8 doses)
Study: 28941216
Drug: ABT-122 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-122 (all doses)
Study: 23286311
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of memantine daily
Study: 19154996
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 (200 mg daily from 20 weeks of pregnancy until delivery)
Study: 19154996
Drug: Placebo (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (daily from 20 weeks of pregnancy until delivery)
Study: 11704369
Drug: heparin-coated beStent
Approvals — FDA: no, EMA: no, PMDA: no
Description: heparin-coated beStent
Study: 7893584
Drug: Isoprenaline (0.25-8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoprenaline (0.25-8 micrograms) and Metoprolol (0.5-8 mg) administered intravenously
Study: 3148787
Drug: Insulin alone
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin alone (group A; n = 8)
Study: 3148787
Drug: 3.5 mg
Normalized name: niacin 13.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.5 mg b.i.d. glibenclamide plus small amounts of intermediate insulin (group B; n = 8)
Study: 27546885
Drug: Trebananib plus
Normalized name: Trebananib
DrugBank: Trebananib (DB12056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trebananib plus weekly paclitaxel (80mg/m², 3 weeks on/1 week off)
Study: 27546885
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus weekly paclitaxel (80mg/m², 3 weeks on/1 week off)
Study: 27546885
Drug: Trebananib plus
Normalized name: Trebananib
DrugBank: Trebananib (DB12056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trebananib plus weekly paclitaxel (80mg/m², 3 weeks on/1 week off) in patients with ascites
Study: 27546885
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus weekly paclitaxel (80mg/m², 3 weeks on/1 week off) in patients with ascites
Study: 24655690
Drug: Ticagrelor 90
Normalized name: ticagrelor 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor 90 mg twice daily with low dose ASA
Study: 24655690
Drug: Ticagrelor 60
Normalized name: ticagrelor 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor 60 mg twice daily with low dose ASA
Study: 24655690
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo with low dose ASA
Study: 17101285
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily 24 microg formoterol in the morning
Study: 17101285
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily 12 microg formoterol in the morning and evening
Study: 14644833
Drug: SprayGel treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: SprayGel treatment
Study: 11034574
Drug: Oral 5‐aminolaevulinic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 5‐aminolaevulinic acid (ALA) 30 mg/kg
Study: 8836705
Drug: roxatidine 150
Normalized name: roxatidine 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: roxatidine 150 mg
Study: 8495155
Drug: 193 mbar
Approvals — FDA: no, EMA: no, PMDA: no
Description: 193 mbar treatment in hyperbaric chamber
Study: 8495155
Drug: 20 mbar
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mbar control treatment
Study: 24746956
Drug: Cash-based reinforcement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cash-based reinforcement therapy (CBRT)
Study: 23842010
Drug: Agomelatine (25-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agomelatine (25-50 mg/d by mouth)
Study: 17926007
Drug: RT +/-
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT +/- chemotherapy
Study: 10847258
Drug: Irbesartan (angiotensin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan (angiotensin II receptor blocker), once-daily treatment
Study: 29781089
Drug: Topical piperine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical piperine combined with NB‐UVB
Study: 29781089
Drug: Topical piperine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical piperine
Study: 24895382
Drug: Land-based rehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Land-based rehabilitation treatment
Study: 20361253
Drug: Pegylated liposomal
Normalized name: doxorubicin HCl pegylated liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated liposomal doxorubicin (PLD) 40 mg/m(2) every 28 days for six cycles
Study: 11949773
Drug: Emedastine 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emedastine 2 mg twice daily
Study: 11949773
Drug: Emedastine 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emedastine 4 mg twice daily
Study: 11949773
Drug: Alcohol (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.05 g/dl)
Study: 10085470
Drug: Capsule A
Normalized name: capsule administration aid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule A (5 mg MLT)
Study: 10085470
Drug: Capsule B
Normalized name: Emend 80mg Capsule BiPack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule B (10 mg MLT)
Study: 10085470
Drug: Capsule C
Normalized name: LIQUID IN CAPSULE CONTAINER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule C (10 mg MLT)
Study: 30522722
Drug: Pooled monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pooled monotherapy
Study: 27015912
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 supplementation (3000 IU daily for 12 weeks via oral spray solution)
Study: 25885424
Drug: Diuretic dose
Normalized name: benazepril and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic dose adjustment according to the AAD and nonpharmacologic management (fluid and sodium restriction) with four telephone calls over 30 days.
Study: 25885424
Drug: Standard diuretic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard diuretic dose adjustment by a physician during the first trial visit without telephone follow-up.
Study: 9735580
Drug: Behavior therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavior therapy with initial weight loss
Study: 9735580
Drug: Behavior therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavior therapy with weight-loss goals
Study: 9735580
Drug: Behavior therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavior therapy with achieved weight goals
Study: 7817735
Drug: Medical abortion
Normalized name: ABSORPTION BASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical abortion (mifepristone 600 mg followed 48 h later by gemeprost 1 mg vaginal pessary)
Study: 3186088
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg ampicillin orally every 6 hours for 10 days
Study: 3186088
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg erythromycin orally every 6 hours for 10 days
Study: 51533
Drug: Candicidin therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candicidin therapy
Study: 25474502
Drug: Core-Stability (CS)
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Core-Stability (CS) exercises plus myofascial trigger-point (MTrP) therapy
Study: 9096993
Drug: Somatulin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatulin (30 mg) administered via intramuscular injections every 10 days for 9 months
Study: 9096993
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered via intramuscular injections every 10 days for 9 months
Study: 31412056
Drug: Motor imagery
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Motor imagery practice (MIp): 15 minutes per day, 5 days per week in addition to routine physical therapy
Study: 31412056
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CON): routine physical therapy alone
Study: 27295868
Drug: Abrasivity-matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abrasivity-matched placebo formulation (0% CSPS)
Study: 17511229
Drug: H2-receptor antagonists
Normalized name: H2-receptor antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2-receptor antagonists (H2RAs)
Study: 17511229
Drug: On-demand treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-demand treatment with H2RA
Study: 12456911
Drug: Intranasal flunisolide
Normalized name: Flunisolide
DrugBank: Flunisolide acetate (DB14662)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal flunisolide therapy (200 micro g twice a day)
Study: 10480618
Drug: Acetoacetate (AA)
Normalized name: ethyl acetoacetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetoacetate (AA) treatment in normal RBCs (37 degrees C for 24 h)
Study: 10480618
Drug: BHB treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: BHB treatment in normal RBCs
Study: 10480618
Drug: ACE treatment
Normalized name: DIMETHICONE 1.5 g in 100 mL TOPICAL CREAM [NIGHTLY FACE TREATMENT - DIMETHICONE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE treatment in normal RBCs
Study: 31800067
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of β‐blockers
Study: 11895556
Drug: 20 microg
Normalized name: Calcifediol 20 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 microg vaccine (Genhevac-B)
Study: 11895556
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 20 microg vaccine (Genhevac-B) and 9 MU interferon alpha-2b (Roferon-A)
Study: 9469336
Drug: r-metHu granulocyte
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: r-metHu granulocyte colony-stimulating factor (G-CSF) during continuation therapy
Study: 9469336
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no G-CSF) during induction phase
Study: 9469336
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no G-CSF) during continuation therapy
Study: 17214176
Drug: Human lymphoblastoid
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human lymphoblastoid IFN alpha (Wellferon‐R) at a dosage of 5 MU, thrice weekly for 4 months
Study: 23024438
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg melatonin nightly for 3 weeks
Study: 19646075
Drug: Pharmacists' interventions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacists' interventions in repeat prescribing, including a pharmacist's interview and annual medication data transfer to prescribing physician.
Study: 17544597
Drug: Neoadjuvant androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant androgen deprivation therapy
Study: 14712425
Drug: Worsened renal
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Worsened renal function (creatinine level increase > or = 0.3 mg/dL) during HERS
Study: 11252010
Drug: New combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: New combination regimens in phase II cancer clinical trials
Study: 11252010
Drug: Proposed adjustment
Normalized name: Propoven
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Proposed adjustment method for standard therapy outcomes
Study: 8496534
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy administered to 55 patients 3.2 +/- 2.1 hours after the onset of symptoms.
Study: 8496534
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (49 patients) without thrombolytic therapy.
Study: 3573270
Drug: 400 mL
Normalized name: Lantidra 400 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mL of autologous, previously frozen deglycerolized RBCs
Study: 3573270
Drug: 100 mL
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mL of saline solution
Study: 29596102
Drug: Intrathecal clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal clonidine 75 µg
Study: 29596102
Drug: Intravenous clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous clonidine 75 µg
Study: 27912953
Drug: Herbal mouthwash
Normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal mouthwash (Matricaria recutita and Mentha piperita), used three times daily for at least 30 seconds, starting one week before HSCT.
Study: 27912953
Drug: Placebo mouthwash,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo mouthwash, used three times daily for at least 30 seconds, starting one week before HSCT.
Study: 18301905
Drug: BTX-A injection
Normalized name: BTX-A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: BTX-A injection
Study: 12585101
Drug: Xuesaitong (XST)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuesaitong (XST) soft capsule
Study: 9817163
Drug: High molecular
Normalized name: dextran, high molecular weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: High molecular weight agents in powder form (two concentrations administered: half and double the one that caused a 20% fall in FEV1)
Study: 7714943
Drug: ampicillin/sulbactam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: ampicillin/sulbactam (1 g ampicillin/0.5 g sulbactam) plus 1 g probenecid orally
Study: 7714943
Drug: ceftriaxone (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: ceftriaxone (250 mg)
Study: 2720576
Drug: Controlled-release morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release morphine sulfate tablets (MS Contin) given every 12 hours
Study: 2720576
Drug: Controlled-release morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release morphine sulfate tablets (MS Contin) given every 8 hours
Study: 28355890
Drug: Expressive writing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expressive writing about thoughts and feelings specific to lymphedema and its treatment
Study: 28355890
Drug: Writing about
Normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Writing about daily activities (control)
Study: 25583588
Drug: Ai Chi
Normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ai Chi aquatic therapy programme
Study: 23338547
Drug: Individualized and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized and supervised exercise program for pelvic floor muscles (PFM), 8 weeks, twice a week
Study: 19143690
Drug: Tramadol 3
Normalized name: TRAMADOL 300MG (RYZOLT) SA TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 3 mg.kg(‐1)
Study: 19143690
Drug: Pethidine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pethidine 0.5 mg.kg(‐1)
Study: 15481276
Drug: R-salbutamol (0.63
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-salbutamol (0.63 mg inhaled three times daily for 1 week)
Study: 15481276
Drug: R,S-salbutamol (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: R,S-salbutamol (1.25 mg inhaled three times daily for 1 week)
Study: 9272411
Drug: Foscarnet administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foscarnet administered as an infusion twice daily (BID)
Study: 9272411
Drug: Foscarnet administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foscarnet administered as an infusion thrice daily (TID)
Study: 7935029
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated oestrogens (oCE) + dydrogesterone (DYDR)
Study: 7935029
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated oestrogens (oCE) + norethisterone acetate (NETA)
Study: 7935029
Drug: Transdermal oestradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal oestradiol (tdE2) + dydrogesterone (DYDR)
Study: 3286509
Drug: Ciprofloxacin (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (1,000 mg daily)
Study: 3286509
Drug: Norfloxacin (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin (800 mg daily)
Study: 27362908
Drug: Diluted vasopressin
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diluted vasopressin solution (20 U in 400 ml normal saline)
Study: 27362908
Drug: Concentrated vasopressin
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concentrated vasopressin solution (20 U in 60 ml normal saline)
Study: 23775057
Drug: Ziprasidone 320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone 320 mg/d
Study: 21911976
Drug: H. pylori
Normalized name: H. PYLORI AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. pylori treatment group (amoxicillin, clarithromycin, omeprazole for 2 weeks)
Study: 11573520
Drug: Nicorandil (HD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil (HD group: 0.08 mg kg(‐1) bolus and 0.08 mg kg(‐1) h(‐1) continuous infusion)
Study: 11573520
Drug: Nicorandil (LD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil (LD group: 0.04 mg kg(‐1) bolus and 0.04 mg kg(‐1) h(‐1) continuous infusion)
Study: 28819993
Drug: Lactobacillus helveticus-fermented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus helveticus-fermented milk drink (190 g/day)
Study: 28248054
Drug: Testosterone replacement
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone replacement therapy (50 mg of testosterone as a 1% topical gel Androgel for 12 weeks postoperatively)
Study: 28248054
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no testosterone replacement therapy)
Study: 28248054
Drug: Testosterone replacement
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone replacement therapy (50 mg of testosterone as a 1% topical gel Androgel)
Study: 24304332
Drug: Verapamil penile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil penile injections (12 total injections for six months and subsequently every month for twelve months: total 24 injections) + Iontophoresis with Verapamil/daily + blueberries 160mg/daily + propolis 600mg/daily + Vitamin E 600mg/daily + topical Diclofenac/daily
Study: 24304332
Drug: Verapamil penile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil penile injections (and associated treatments)
Study: 18157071
Drug: Valacyclovir 1
Normalized name: valacyclovir 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valacyclovir 1 g daily for 60 days
Study: 16877730
Drug: Letrozole (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole (2.5 mg daily for 6 months)
Study: 16877730
Drug: Letrozole plus
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole plus oral cyclophosphamide (50 mg daily for 6 months)
Study: 16877730
Drug: Letrozole plus
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole plus oral cyclophosphamide
Study: 1390121
Drug: 8-methoxypsoralen (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-methoxypsoralen (0.6 mg/kg)
Study: 1390121
Drug: 5-methoxypsoralen (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-methoxypsoralen (1.2 mg/kg)